What is pantoprazole used for?

Indications and Usage, quoted from the label by Torrent Pharmaceuticals Limited (ANDA090074). Cross-references to other label sections are left out.

Pantoprazole sodium delayed-release tablets are indicated for:

Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD)

Pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established.

Maintenance of Healing of Erosive Esophagitis

Pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months.

Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome

Pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome.

Source: DailyMed label, set id 9c983da1-a8e0-479e-8816-5d5668ea242e, version 27, effective February 5, 2026. NDC 13668-096, one of 124 listings for this product.

Indications and Usage, quoted from the label by Camber Pharmaceuticals, Inc. (ANDA213778). Cross-references to other label sections are left out.

Pantoprazole sodium for injection is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Limitations of Use The safety and effectiveness of pantoprazole sodium for injection for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients. Pediatric use information is approved for Pfizer Inc.'s PROTONIX ®I.V. (pantoprazole sodium) for Injection. However, due to Pfizer Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

Source: DailyMed label, set id 1bb94d3c-8bc3-4193-9dd8-e9a22066707c, version 5, effective August 31, 2026. NDC 31722-204, one of 11 listings for this product.